From the Guidelines
Jardiance (empagliflozin) is recommended for adults with type 2 diabetes at an initial dose of 10 mg once daily, taken in the morning with or without food, as it has been shown to improve glycemic control and reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease 1.
Key Considerations
- The dose can be increased to 25 mg once daily if additional glycemic control is needed and the initial dose is well tolerated.
- Patients should maintain adequate hydration while taking Jardiance.
- Jardiance works by inhibiting sodium-glucose cotransporter-2 (SGLT2) in the kidneys, which reduces reabsorption of filtered glucose and lowers blood glucose levels through increased urinary glucose excretion.
- Renal function should be assessed before starting therapy, and Jardiance is not recommended for patients with severe renal impairment (eGFR less than 45 mL/min/1.73 m²) for glycemic control, as stated in the 2020 expert consensus decision pathway 1 and further supported by the 2022 consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) 1.
Important Warnings and Precautions
- Jardiance should not be used in patients with type 1 diabetes or for treatment of diabetic ketoacidosis.
- Common side effects include urinary tract infections, genital mycotic infections, and increased urination.
- Patients should be monitored for hypoglycemia, especially when used with insulin or insulin secretagogues, and for signs of ketoacidosis, which can occur even with normal blood glucose levels.
Dose Modifications and Contraindications
- Dose modifications are necessary for patients with renal impairment, with a maximum dose of 10 mg daily for patients with eGFR less than 45 mL/min/1.73 m² 1.
- Jardiance is contraindicated in patients on dialysis and in patients with severe renal impairment (eGFR less than 45 mL/min/1.73 m²) for glycemic control 1.
From the FDA Drug Label
1 INDICATIONS AND USAGE
Jardiance is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
2 DOSAGE AND ADMINISTRATION
The recommended dose of Jardiance is 10 mg once daily, taken in the morning, with or without food.
The recommended use and dosage of Jardiance (empagliflozin) in patients with type 2 diabetes is as an adjunct to diet and exercise to improve glycemic control, with a recommended dose of 10 mg once daily. The dose can be taken in the morning, with or without food 2.
- The dose is 10 mg once daily.
- It can be taken with or without food.
- It is used to improve glycemic control in adults with type 2 diabetes mellitus.
From the Research
Recommended Use and Dosage of Jardiance (Empagliflozin)
- Jardiance (empagliflozin) is a sodium glucose cotransporter-2 (SGLT2) inhibitor used for the treatment of adults with type 2 diabetes 3.
- The recommended dosage of Jardiance is 10 mg or 25 mg once daily, administered orally 4.
- Jardiance can be used as monotherapy or as a component of combination therapy with other antidiabetic agents 3.
Efficacy and Safety
- Empagliflozin has been shown to reduce cardiovascular mortality and morbidity in patients with type 2 diabetes and established cardiovascular disease [(5,6,4)].
- The drug has a moderate glucose-lowering effect, with a reduction in HbA1c of about 0.5% compared to placebo 5.
- Empagliflozin is generally well tolerated, with common adverse effects including genital infections, kidney failure, and diabetic ketoacidosis [(5,6)].
Patient Selection
- Jardiance is suitable for patients with type 2 diabetes who require an additional antidiabetic medication to attain their glycaemic goal, particularly those at high cardiovascular risk 3.
- The drug may be beneficial for patients with heart failure with reduced ejection fraction (HFrEF) and high risk for cardiovascular events 7.
- However, the evidence for the use of empagliflozin in patients without established cardiovascular disease is limited 6.